ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SNG Synairgen Plc

4.675
0.155 (3.43%)
25 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.155 3.43% 4.675 4.35 5.00 - 25,623 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.52 9.1M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.52p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.10 million. Synairgen has a price to earnings ratio (PE ratio) of -0.52.

Synairgen Share Discussion Threads

Showing 25051 to 25073 of 99175 messages
Chat Pages: Latest  1003  1002  1001  1000  999  998  997  996  995  994  993  992  Older
DateSubjectAuthorDiscuss
28/8/2020
07:56
Joe it will come 😎
d1nga
28/8/2020
07:54
these papers are all very well, but I - like I'm sure most s'holders - would like to see a positive application of them through further progression/approval/commercialisation of SNG001!
sloppyjoe2
28/8/2020
07:47
Fauci seems to be a strong advocate of early intervention in C-19.
I wonder if he’s been in contact with Holgate?

wetdream
28/8/2020
07:38
All the above papers are from the last 24hrs.
waterloo01
28/8/2020
07:37
Yet another positive paper. Don't give up just before the finish!

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison

Notably, higher IFN-λ levels in COVID-19 patients correlate with lower viral load in bronchial aspirates and faster viral clearance, and a higher IFN-λ:type I IFN ratio with improved outcome of critically ill patients. Moreover, altered cytokine patterns in COVID-19 patients correlate with longer hospitalization time and higher incidence of critical disease and mortality compared to flu. These data point to an untuned antiviral response in COVID-19 contributing to persistent viral presence, hyperinflammation and respiratory failure.

waterloo01
28/8/2020
07:36
Thanks to makendon




Indeed, many companies that have found they can apply IP and business capacity to fighting the virus have seen their share prices rocket – UK small-cap Synairgen, for instance, saw its shares soar more than 1000% between the start of the year and mid-April as investors piled in on its plans to develop a potential treatment for coronavirus.

Nevertheless, while some valuations in the US might have edged too high, in the UK that certainly is not yet the case. Indeed, we are currently seeing a trend of US institutional investors coming in to buy what they see as undervalued UK biotech companies.

waterloo01
28/8/2020
07:31
SNG just too risky. Took profits and moved into DNL a few weeks ago. Much more upside potential there IMHO.
walkermike1
28/8/2020
07:28
I take no pleasure in being right this morning.
sloppyjoe2
Chat Pages: Latest  1003  1002  1001  1000  999  998  997  996  995  994  993  992  Older

Your Recent History

Delayed Upgrade Clock